NIKKEI 225
27,049.47 +178.17 (+0.66%) HANG SENG
22,418.97 +189.47 (+0.85%) CRUDE OIL
111.75 +2.18 (+1.99%) GOLD FUTURES
1,820.50 -4.30 (-0.24%) DOW
30,959.25 -479.01 (-1.52%) BTC-GBP
16,643.68 -549.81 (-3.20%)
Adicet Bio, Inc. (0HX7.L)
| Previous close | 12.73 |
| Open | 14.14 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 14.14 - 14.14 |
| 52-week range | 14.14 - 14.14 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 728.561M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings date | 09 Mar 2022 - 14 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Adicet Bio to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif. & BOSTON, June 21, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in June.
- Business Wire
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
REDWOOD CITY, Calif. & BOSTON, June 06, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced emerging positive safety and efficacy data from the Company’s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (NHL) in an oral presentation at the 2022 American Society of Clinica
- Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. & BOSTON, June 03, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on May 31, 2022 (the "Grant Date") under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in May 2022.
